These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34034278)

  • 21. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.
    Panés J; Loftus EV; Higgins PDR; Lindsay JO; Zhou W; Yao X; Ilo D; Phillips C; Tran J; Sanchez Gonzalez Y; Vermeire S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1421-1430. PubMed ID: 36645051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study.
    Yu J; Park SJ; Kim HW; Lim YJ; Park J; Cha JM; Ye BD; Kim TO; Kim HS; Lee HS; Jung SY; Kim Y; Choi CH
    Gut Liver; 2022 Sep; 16(5):764-774. PubMed ID: 34959224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission.
    Viazis N; Pontas C; Manolakis A; Karampekos G; Tsoukali E; Galanopoulos M; Koustenis K; Archavlis E; Christidou A; Gazouli M; Mantzaris GJ
    Acta Gastroenterol Belg; 2021; 84(3):423-428. PubMed ID: 34599566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.
    Athanassiou P; Kotrotsios A; Kallitsakis I; Bounas A; Dimitroulas T; Garyfallos A; Tektonidou MG; Vosvotekas G; Livieratos A; Petrikkou E; Katsifis G
    Qual Life Res; 2022 May; 31(5):1385-1399. PubMed ID: 34839451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
    Pugliese D; Privitera G; Rogai F; Variola A; Viola A; Laterza L; Privitera AC; Allocca M; Bossa F; Cappello M; Daperno M; Lorenzon G; Mazzuoli S; Principi M; Sablich R; Moser L; Ferronato A; Traini S; Tapete G; Bodini G; Di Girolamo M; Grossi L; Mocci G; Ricci C; Saibeni S; Festa S; Spagnuolo R; Cortelezzi CC; Mocciaro F; Rizzello F; Armuzzi A;
    United European Gastroenterol J; 2021 Feb; 9(1):102-109. PubMed ID: 33203342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit.
    Hyams JS; Chan D; Adedokun OJ; Padgett L; Turner D; Griffiths A; Veereman G; Heyman MB; Rosh JR; Wahbeh G; Strauss R
    Inflamm Bowel Dis; 2017 Dec; 23(12):2227-2237. PubMed ID: 29140944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
    Magro F; Lopes S; Silva M; Coelho R; Portela F; Branquinho D; Correia L; Fernandes S; Cravo M; Caldeira P; Sousa HT; Patita M; Lago P; Ramos J; Afonso J; Redondo I; Machado P; Cornillie F; Lopes J; Carneiro F;
    J Crohns Colitis; 2019 Oct; 13(11):1387-1393. PubMed ID: 30989180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.
    Eriksson C; Visuri I; Vigren L; Nilsson L; Kärnell A; Hjortswang H; Bergemalm D; ; Almer S; Hertervig E; Karlén P; Strid H; Halfvarson J
    Scand J Gastroenterol; 2021 Nov; 56(11):1304-1311. PubMed ID: 34415803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study.
    Van Assche G; Peyrin-Biroulet L; Sturm A; Gisbert JP; Gaya DR; Bokemeyer B; Mantzaris GJ; Armuzzi A; Sebastian S; Lara N; Lynam M; Rojas-Farreras S; Fan T; Ding Q; Black CM; Kachroo S
    Dig Liver Dis; 2016 Jun; 48(6):592-600. PubMed ID: 26935454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
    J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation.
    Stern S; Ward AJ; Saint-Laurent Thibault C; Camacho F; Rahme E; Naessens D; Aumais G; Bernard EJ; Bourdages R; Cohen A; Pare P; Dyrda P
    J Med Econ; 2018 Jan; 21(1):27-37. PubMed ID: 28830258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
    Toor K; Druyts E; Jansen JP; Thorlund K
    J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
    Tursi A; Mocci G; Elisei W; Allegretta L; Colucci R; Della Valle N; De Medici A; Faggiani R; Ferronato A; Forti G; Larussa T; Lorenzetti R; Luzza F; Penna A; Pranzo G; Rodinò S; Sacco R; Sebkova L; Zampaletta C; Graziosi C; Picchio M; Bergna IMB; Maconi G
    J Gastrointestin Liver Dis; 2021 Dec; 30(4):456-461. PubMed ID: 34812437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.
    Tursi A; Allegretta L; Buccianti N; Della Valle N; Elisei W; Forti G; Faggiani R; Gallina S; Hadad Y; Larussa T; Lauria A; Luzza F; Lorenzetti R; Mocci G; Penna A; Polimeni N; Pranzo G; Ricciardelli C; Zampaletta C; Picchio M
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):239-244. PubMed ID: 28922435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.
    Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A
    J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
    Dignass A; Waller J; Cappelleri JC; Modesto I; Kisser A; Dietz L; DiBonaventura M; Wood R; May M; Libutzki B; Bargo D
    J Med Econ; 2020 Apr; 23(4):415-427. PubMed ID: 31858853
    [No Abstract]   [Full Text] [Related]  

  • 39. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.
    Reinisch W; Colombel JF; Gibson PR; Rutgeerts P; Sandborn WJ; Tarabar D; Huyck S; Khalifa A; Marano C; Philip G; Yao R; Zhang H; Cornillie F
    Inflamm Bowel Dis; 2019 Jan; 25(1):163-171. PubMed ID: 29982631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.